From 1/3/2024, looking back across 17 Month-Ends for GTH, Percentage Change of Average Monthly Price had More Positives (54%) while Percentage Change of Average Monthly Volume had More Positives (94%) $GTH #GTH #GTHStock #TickerDD https://www.youtube.com/watch?v=GbQPbKkuebk
$GTH Genetron Health Announces Completion of Going Private Transaction
https://www.stocktitan.net/news/GTH/genetron-health-announces-completion-of-going-private-6a8mza0jwjuu.html
From 3/19/2024, looking back across 22 Month-Ends for GTH, Percentage Change of Average Monthly Price had More Positives (67%) while Percentage Change of Average Monthly Volume had All Positives (100%) $GTH #GTH #GTHStock #TickerDD https://www.youtube.com/watch?v=5H1MU_Y_LLY
$GTH Genetron Health Announces Shareholders’ Approval of Merger Agreement
https://www.stocktitan.net/news/GTH/genetron-health-announces-shareholders-approval-of-merger-erfigpnqr4da.html
$GTH | Genetron (GTH US): Wide Spread Ahead of the 21 February Vote
"Despite the light offer, this is a done deal. At the last close price and end of March completion, the gross and annualised spread is 7.7% and 45.5%, respectively." - Arun George (Global Equity Research Ltd)
Key Points:
* Genetron Holdings Ltd (GTH US) shareholders will vote on the consortium’s US$4.08 per ADS offer on 21 February. The offer is light in comparison to historical trading ranges.
* Completion is conditional on shareholder approval, dissenting shareholders representing less than 15% of outstanding shares and regulatory approvals (NDRC, MoC and SAFE).
* Despite the light offer, the completion conditions should be met. At the last close price and end of March completion, the gross and annualised spread is 7.7% and 45.5%, respectively.
Read more: https://www.smartkarma.com/insights/genetron-gth-us-wide-spread-ahead-of-the-21-february-vote
$GTH | Genetron Holdings (GTH US): Clear Diagnosis
"This is done and could be wrapped up early-to-mid March . Trading at an attractive gross spread of 7.7%. If small, illiquid arbs are your thing, get involved." - David Blennerhassett (Quiddity Advisors)
Key Points:
* Back on the 11th October 2023, Genetron Holdings Ltd (GTH US), a precision oncology platform, entered into a definitive take-private transaction, at $4.08/ADS, a 15% premium to undisturbed.
* The EGM for shareholders to vote on the transaction will be held on the 21 February. The record date is the 9 Feb.
* This merger requires approval from at least two-thirds of the votes cast, and 59.7% are supportive. Trading at a gross spread of 7.7%. This is a clean deal.
Read more: https://www.smartkarma.com/insights/genetron-holdings-gth-us-clear-diagnosis
$RDGL FDA granted Breakthrough Device Designation (BDD) for their medical device RadioGel and they are on the edge of submitting the Investigational Device Exemption (IDE) to the FDA to start human clinical trials $GTH $FENC $ORIC
$YI $GTH Genetron had a non binding a bid August last year and recently turned that into a definitive agreement. I think YI had their non binding offer in September last year. So let's see what happens. It is strange that this is taking so long.
@JohnTill Got a little lucky with timing as i bought some $HOLI just below 19. Looking to add some more if it drops back closer to that level. John, do you follow $GTH ?
